Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis

Background. Few data are available on the safety and efficacy of sorafenib in patients with multifocal hepatocellular carcinoma (HCC) and advanced liver cirrhosis. Methods. Between May 2006 and December 2007, we treated 59 patients (Child-Pugh class A/B/C, 26/23/10) with unresectable HCC with sorafenib (daily target dose,400mgtwicedaily).Datawerecollectedretrospectively. Survival curves were calculated via the Kaplan– Meier method. Results. One patient (Child-Pugh class B) had a partial response, 14 patients (Child-Pugh class A/B/C,